Laser Treatment of the Crystalline Lens

Inclusion Criteria: * Subjects must sign and be given a copy of the written informed consent form. * Subjects must have elected to undergo lens extraction and foldable monofocal IOL implantation (ideally of the same type), and then elect to have the LensAR laser surgery. * Subjects must be willing and able to return for scheduled follow-up examinations for a minimum of 12 months after surgery. * Central 8 mm of clear cornea without vascularization. Exclusion Criteria: * Subjects with prior anterior segment or vitreo-retinal surgical intervention in the eye to be treated. * Subjects with lenticular cataracts with nuclear grading greater than Grade 4 on the LOCS III scale. * Subjects who cannot attain ocular dilation of 7.0 mm. * Subjects with anterior segment pathology in the eye to be treated that is not directly improved by lens extraction and IOL implantation. * Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease or any corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in the eye to be treated. * Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye to be treated. * Subjects with a history of severe dry eye not responding to therapy. * Subjects with macular degeneration, history of retinal detachment, or any other fundus findings that would pose a risk to safety or an acceptable visual outcome in the eye to be treated. * Subjects with a history of herpes zoster or herpes simplex keratitis. * Subjects who have a history of steroid-responsive rise in intraocular pressure, glaucoma, or are a glaucoma suspect. * Subjects with diabetic retinopathy, autoimmune disease, connective tissue disease, pseudoexfoliation syndrome, or clinically significant atopic syndrome. * Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immuno-compromised subjects. * Subjects who are using ophthalmic medication(s) other than artificial tears for treatment of ocular pathology including ocular allergy. * Subjects using systemic medications with significant ocular side effects. * Subjects who are pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control. * Subjects with known sensitivity to planned study concomitant medications. * Subjects who are participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.